Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa-Reference-Cited by-同舟云学术

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

Published:2003-08 Issue:9384 Volume:362 Page:617-619
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Marin David,Marktel Sarah,Szydlo Richard,Klein John P,Bua Marco,Foot Nicola,Olavarria Eduardo,Shepherd Pat,Kanfer Edward,Goldman John M,Apperley Jane F

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001

2. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

3. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

4. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia;Shah;Cancer Cell,2002

5. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82;Haematologica;2012-05-01

2. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed;Haematologica;2011-08-22

3. Moving towards dose individualization of tyrosine kinase inhibitors;Cancer Treatment Reviews;2011-06

4. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone;Leukemia Research;2011-01

5. Differential diagnosis – chromosomal/molecular changes;Atlas of Differential Diagnosis in Neoplastic Hematopathology;2008-09-24